• In late January 2026, Halozyme Therapeutics raised its 2026 revenue guidance to a range of US$1.71 billion to US$1.81 billion and projected 2025 revenue between US$1.39 billion and US$1.40 billion, indicating strong anticipated business momentum.
• Analysts have highlighted the ENHANZE drug‑delivery platform’s expansion into areas such as inflammatory bowel disease and obesity as a material driver of Halozyme’s long‑term growth opportunity beyond oncology.
• We’ll now examine how the upgraded revenue guidance and ENHANZE’s expansion into larger disease markets shape Halozyme’s broader investment narrative.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

What Is Halozyme Therapeutics' Investment Narrative?

For Halozyme, you really have to buy into the idea that ENHANZE can keep scaling across multiple partners and indications, while the company manages its balance sheet and capital returns responsibly. The sharp uplift in 2026 revenue guidance to US$1.71 billion to US$1.81 billion, coming soon after earlier upgrades, reinforces the near term catalyst of faster ENHANZE adoption and helps explain the solid share price gains over the past year. It also raises the bar: guidance is now a key swing factor, and any wobble in partner launches, regulatory timelines or pricing could quickly become the main risk. The expanding buyback and extended credit facility add financial flexibility, but they also keep attention on leverage and execution quality as Halozyme leans further into its royalty driven model.

However, investors should be aware of how much depends on ENHANZE’s partners delivering as planned. Halozyme Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Eight Simply Wall St Community fair value estimates for Halozyme range from about US$77 to just over US$201, showing how far apart individual views can be. Set against Halozyme’s sharply upgraded multi year revenue guidance, this spread underlines why it helps to weigh both the upside tied to ENHANZE’s expansion and the execution risk around partner uptake and a leveraged balance sheet when you are comparing different expectations for the business.

Explore 8 other fair value estimates on Halozyme Therapeutics - why the stock might be worth over 2x more than the current price!

Build Your Own Halozyme Therapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Halozyme Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Halozyme Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Halozyme Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• Outshine the giants: these 24 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.